MyFinsight
Home
Blog
About
Contact
Download
Download image
Gross proceeds from
issuance of 2030...
$460,000K
Net income (loss)
$124,453K
Proceeds from issuance of
warrants
$67,390K
Net proceeds from
stock option...
$47,501K
Proceeds from pelthos
investors bridge loans
$6,910K
Share-based compensation
$46,849K
Depreciation of fixed assets
and amortization of...
$33,775K
Deferred income taxes,
net
-$22,684K
Impairment loss of
financial royalty assets
$6,197K
Accounts payable and
accrued liabilities
$5,882K
Inventory
-$4,988K
Income taxes
receivable and payable
-$2,667K
Lease amortization
expense
$1,942K
Other
$1,688K
Amortization of debt discount
and issuance fees
$1,273K
Change in estimated
fair value of...
-$860K
Net cash provided by
(used) in financing...
$428,223K
Net cash provided by
operating activities
$49,359K
Effect of exchange rate
changes on cash and cash...
$2,360K
Canceled cashflow
$153,578K
Canceled cashflow
$203,899K
Net increase
(decrease) in cash and cash...
$102,620K
Canceled cashflow
$377,322K
Purchase of 2030
convertible senior notes...
$113,250K
Debt discount and
payment of debt issuance...
$15,528K
Repurchase of common stock
$15,000K
Taxes paid related to
net share...
$9,599K
Payments to cvr holders
$174K
Payments under finance
lease obligations
$27K
Proceeds from maturity of
short-term investments
$217,700K
Proceeds from sale of
short-term investments
$159,584K
Proceeds from financial
royalty assets
$10,261K
(gain) loss from change
in fair value of...
$90,670K
Gain on pelthos
transaction
$53,072K
Accounts receivable, net
$21,737K
Gain from short-term
investments
$18,433K
Non-cash income from
financial royalty assets
$8,620K
Accretion of premium on
short-term investments,...
$4,958K
Other assets and
liabilities
$3,887K
Loss (gain) on
derivative instruments
$1,022K
Cecl adjustment to
financial royalty assets
-$922K
Deferred revenue
-$578K
Net cash used in
investing activities
-$377,322K
Canceled cashflow
$387,545K
Purchases of short-term
investments
$726,713K
Purchases of derivatives
$13,792K
Acquisition of financial
royalty assets
$10,862K
Cash outflow on
deconsolidation of lnhc, inc
$8,085K
Cash paid for other
investments
$3,847K
Acquisition of royalty
receivables
$813K
Purchases of property and
equipment
$452K
Cash paid for invios
investment
$303K
Back
Back
Cash Flow
source: myfinsight.com
LIGAND PHARMACEUTICALS INC (LGNXZ)
LIGAND PHARMACEUTICALS INC (LGNXZ)